SEATTLE, WA--(Marketwired - Dec 2, 2014) - Atossa Genetics Inc. (
Rhenus will provide Atossa with logistics services and support throughout European markets from its facilities located in Tilburg,The Netherlands, including warehousing, packaging, shipping, invoicing and collections. The Rhenus global operations include more than 390 locations and 24,000 employees worldwide.
Dr. Steven C. Quay, Chairman, CEO and President, stated, "Rhenus is one of the largest logistics firms in Europe and manages logistics operations for many of Europe's leading medical device and healthcare companies. Contracting with Rhenus is a critical step in our European launch and we look forward to working with them as we commercialize our ForeCYTE Breast Aspirator device in select European markets."
A.J.L. van Erven, Senior Vice President, Rhenus Contract Logistics Holding B.V., commented, "We are excited about Atossa Genetics and adding them to our expanding family of medical device manufacturers. We look forward to a rewarding business relationship as we provide vital logistics and support services in the European markets and assist Atossa with the commercialization of their innovative medical products."
About Atossa Genetics
Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For additional information, please visit www.atossagenetics.com.
About Rhenus
Turnover at the Rhenus Group tops EUR 4.1 billion, making it one of the logistics service companies with global operations. Rhenus has business locations at more than 390 locations worldwide and employs 24,000 people. The Rhenus business areas -- Contract Logistics, Freight Logistics, Port Logistics and Public Transport -- manage complex supply chains and provide a wealth of innovative value-added services. For additional information, please visit www.nl.rhenus.com.
Forward-Looking Statements
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory clearances needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls of products, the efficacy of Atossa's products and services, performance of distributors, estimated future expenses and cash needs, whether Atossa can launch in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.